

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 26, 2025

South Texas Accelerated Research Therapeutics

RRID:SCR_004867

Type: Tool

Proper Citation

South Texas Accelerated Research Therapeutics (RRID:SCR_004867)

Resource Information

URL: <http://www.startthecure.com/>

Proper Citation: South Texas Accelerated Research Therapeutics (RRID:SCR_004867)

Description: South Texas Accelerated Research Therapeutics (START) directs clinical trials of novel anticancer agents using a high quality and innovative information technology infrastructure to ensure accurate and rapid clinical trials in a setting that emphasizes personalized and compassionate clinical care. START's head office is located in San Antonio, Texas, in the heart of the South Texas Medical Center. With centers located in San Antonio, Texas and Madrid, Spain, START conducts the world's largest Phase I medical oncology program putting more than 400 patients per year on Phase I trials. Patients travel from all over the world to participate in one or more of our Phase I drug trials. START consists of a team of highly trained physicians and staff with extensive experience in Phase I clinical trials research and are nationally recognized as thought leaders in cancer research and drug development. The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients with cancer. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.

Abbreviations: START

Resource Type: research forum portal, portal, data or information resource, disease-related portal, topical portal

Keywords: cancer, clinical, human, clinical trial, clinical research, oncology, drug trial, drug development, anticancer drug

Funding:

Resource Name: South Texas Accelerated Research Therapeutics

Resource ID: SCR_004867

Alternate IDs: nlx_143931

Record Creation Time: 20220129T080227+0000

Record Last Update: 20250426T055737+0000

Ratings and Alerts

No rating or validation information has been found for South Texas Accelerated Research Therapeutics.

No alerts have been found for South Texas Accelerated Research Therapeutics.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 161 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Belus JM, et al. (2025) Couple-Based Intervention to Improve HIV Care Engagement for Women and their Partners in KwaZulu-Natal, South Africa: Outcomes of a Pilot Randomized Controlled Trial. Journal of the International Association of Providers of AIDS Care, 24, 23259582241307694.

Cigler M, et al. (2025) Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting OSBP. Nature chemical biology, 21(2), 193.

Korek M, et al. (2025) Strigolactone insensitivity affects differential shoot and root transcriptome in barley. Journal of applied genetics, 66(1), 15.

Berger AT, et al. (2025) Effect of Delaying High School Start Time on Teen Physical Activity, Screen Use, and Sports and Extracurricular Activity Participation: Results From START. The Journal of school health, 95(1), 70.

Orsini A, et al. (2025) PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic Centers. The Prostate, 85(4), 337.

Lewis J, et al. (2025) PROTOCOL: Non-criminal justice interventions for countering cognitive

and behavioural radicalisation amongst children and adolescents: A systematic review of effectiveness and implementation. *Campbell systematic reviews*, 21(1), e70020.

Parodi López N, et al. (2025) Inter-rater agreement for detection of potentially inappropriate medication according to explicit and implicit STOPP criteria. *British journal of clinical pharmacology*, 91(2), 485.

Sumi T, et al. (2025) Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study. *Cancer immunology, immunotherapy* : CII, 74(2), 39.

Mohsendokht M, et al. (2025) Enhancing maritime transportation security: A data-driven Bayesian network analysis of terrorist attack risks. *Risk analysis : an official publication of the Society for Risk Analysis*, 45(2), 283.

Hendry A, et al. (2025) Learning from the community: iterative co-production of a programme to support the development of attention, regulation and thinking skills in toddlers at elevated likelihood of autism or ADHD. *Research involvement and engagement*, 11(1), 7.

Utzat F, et al. (2025) Meeting Cancer Detection Benchmarks in MRI/Ultrasound Fusion Biopsy for Prostate Cancer: Insights from a Retrospective Analysis of Experienced Urologists. *Cancers*, 17(2).

Łubkowska B, et al. (2024) Recombinant TP-84 Bacteriophage Glycosylase-Depolymerase Confers Activity against Thermostable *Geobacillus stearothermophilus* via Capsule Degradation. *International journal of molecular sciences*, 25(2).

Zorbas C, et al. (2024) A systems framework for implementing healthy food retail in grocery settings. *BMC public health*, 24(1), 137.

Dong Z, et al. (2024) Injectable, thermo-sensitive and self-adhesive supramolecular hydrogels built from binary herbal small molecules towards reusable antibacterial coatings. *RSC advances*, 14(3), 2027.

Hoang TT, et al. (2024) Comprehensive evaluation of smoking exposures and their interactions on DNA methylation. *EBioMedicine*, 100, 104956.

Skrzypczak D, et al. (2024) Recent innovations in fertilization with treated digestate from food waste to recover nutrients for arid agricultural fields. *Environmental science and pollution research international*, 31(29), 41563.

Kummer I, et al. (2024) Polypharmacy and potentially inappropriate prescribing of benzodiazepines in older nursing home residents. *Annals of medicine*, 56(1), 2357232.

Moqadam M, et al. (2024) A Membrane-Assisted Mechanism for the Release of Ceramide from the CERT START Domain. *The journal of physical chemistry. B*, 128(26), 6338.

Gresele P, et al. (2024) Low platelet count at admission has an adverse impact on outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. *Scientific*

reports, 14(1), 14516.

Al-Ghumlas AK, et al. (2024) Ramadan intermittent fasting is associated with improved anticoagulant activity among healthy people: a case-control study. Scientific reports, 14(1), 13855.